Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net loss $ (94,965) $ (11,423)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 76,677 72,612
Non-cash interest 1,944 2,063
Amortization of deferred financing costs 168 175
Losses from investments in investees 11,771 5,147
Equity-based compensation – employees and non-employees 22,292 34,939
Realized loss (gain) on equity securities and disposal of fixed assets (2,683) 943
Change in fair value of derivative instruments (1,969) 5,889
Change in fair value of contingent consideration (4,475) 15,604
Deferred income tax benefit (46,366) (30,982)
Changes in assets and liabilities, net of the effects of acquisitions:    
Accounts receivable, net (13,594) (28,974)
Inventory, net 1,729 (2,726)
Other current assets and prepaid expenses (2,857) (24,310)
Other assets (449) (402)
Accounts payable 12,013 (16,141)
Foreign currency measurement 608 (433)
Deferred revenue (42,142) (56,256)
Accrued expenses and other liabilities (11,892) 36,015
Net cash provided by (used in) operating activities (94,190) 1,740
Cash flows from investing activities:    
Investments in investees (4,625) (9,171)
Acquisition of businesses, net of cash 0 15,878
Purchase of marketable securities (6) (15,631)
Maturities of short-term marketable securities 0 15,634
Proceeds from the sale of property, plant and equipment 3,979 1,082
Acquisition of intangible assets 0 (5,000)
Capital expenditures (32,061) (17,015)
Net cash used in investing activities (32,713) (14,223)
Cash flows from financing activities:    
Proceeds from the exercise of Common Stock options and warrants 1,916 6,112
Borrowings on lines of credit 75,544 15,816
Repayments of lines of credit (20,643) (58,901)
Net cash provided by (used in) financing activities 56,817 (36,973)
Effect of exchange rate changes on cash and cash equivalents 1,715 504
Net decrease in cash and cash equivalents (68,371) (48,952)
Cash and cash equivalents at beginning of period 168,733 193,598
Cash and cash equivalents at end of period 100,362 144,646
SUPPLEMENTAL INFORMATION:    
Interest paid 1,409 2,519
Income taxes paid, net 5,899 8,045
Shares issued upon the conversion of:    
Common Stock options and warrants, surrendered in net exercise 1,546 350
Transition Therapeutics    
Issuance of capital stock for contingent consideration settlement:    
Capital stock issued 0 58,530
OPKO Health Europe    
Issuance of capital stock for contingent consideration settlement:    
Capital stock issued 303 313
OPKO Renal    
Issuance of capital stock for contingent consideration settlement:    
Capital stock issued 0 25,986
Xenetic Biosciences, Inc.    
Issuance of capital stock for contingent consideration settlement:    
Capital stock issued $ 0 $ 4,856